Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

US11512092B2 · kind B2 · utility

Assignee

• Abb Vie Inc. · US

Inventors

• Ayman Allian · Grayslake, US
• Jayanthy Jayanth · Buffalo Grove, US
• Mohamed-Eslam F. Mohamed · Gurnee, US
• Mathew M. Mulhern · Lake Villa, US
• Fredrik Lars Nordstrom · Ridgefield, US
• Ahmed A. Othman · Libertyville, US
• Michael J. Rozema · Kenosha, US
• Lakshmi Bhagavatula · Vernon Hills, US
• Patrick J. Marroum · Springfield, US
• Peter T. Mayer · Libertyville, US
• Ahmad Y. Sheikh · Lake Forest, US
• Thomas B. Borchardt · Kenosha, US
• Ben Klünder · Ludwigshafen, DE

Key dates

• Filing date: May 2, 2022
• Grant date: Nov 29, 2022
• Expiry date: May 2, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).